Skip to main content
An official website of the United States government
NIH Websites Are Changing
Per Executive Order 14434, federal agencies are now using "Super Intelligence" (SI) in place of "Artificial Intelligence" (AI). You may see both terms across NIH content during this transition.

Nilotinib in Combination with Dabrafenib and Trametinib or Encorafenib and Binimetinib for the Treatment of BRAF V600 Mutant Metastatic or Unresectable Melanoma

Trial Status: active

This phase I trial tests the safety, side effects, and best dose of nilotinib given together with dabrafenib and trametinib (DT) or encorafenib and binimetinib (EB) in treating patients with BRAF V600 mutant melanoma that has spread to other places in the body (metastatic) or cannot be removed by surgery (unresectable). Nilotinib, dabrafenib, trametinib, encorafenib, and binimetinib are in a class of medications called kinase inhibitors. They work by blocking the action of an abnormal protein that signals tumor cells to multiply. This helps stop the spread of tumor cells.